[go: up one dir, main page]

ES2194732T3 - Composiciones farmaceuticas orales de liberacion controlada de mesalazina. - Google Patents

Composiciones farmaceuticas orales de liberacion controlada de mesalazina.

Info

Publication number
ES2194732T3
ES2194732T3 ES00935194T ES00935194T ES2194732T3 ES 2194732 T3 ES2194732 T3 ES 2194732T3 ES 00935194 T ES00935194 T ES 00935194T ES 00935194 T ES00935194 T ES 00935194T ES 2194732 T3 ES2194732 T3 ES 2194732T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
mesalazine
oral pharmaceutical
controlled liberation
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00935194T
Other languages
English (en)
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo SpA
Original Assignee
Cosmo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11383159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2194732(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo SpA filed Critical Cosmo SpA
Application granted granted Critical
Publication of ES2194732T3 publication Critical patent/ES2194732T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas orales de liberación controlada que contienen como ingrediente activo el ácido 5-aminosalicílico, que comprenden: a) una matriz lipófila interna constituida por sustancias con un punto de fusión por debajo de 90oC en la que el ingrediente activo está al menos parcialmente englobado; b) una matriz hidrófila externa en la que está dispersa la matriz lipófila; c) opcionalmente otros excipientes.
ES00935194T 1999-06-14 2000-06-08 Composiciones farmaceuticas orales de liberacion controlada de mesalazina. Expired - Lifetime ES2194732T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI001316A ITMI991316A1 (it) 1999-06-14 1999-06-14 Composizioni farmaceutiche orali a rilascio modificato di mesalazina

Publications (1)

Publication Number Publication Date
ES2194732T3 true ES2194732T3 (es) 2003-12-01

Family

ID=11383159

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02026576T Expired - Lifetime ES2262749T3 (es) 1999-06-14 2000-06-08 Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
ES00935194T Expired - Lifetime ES2194732T3 (es) 1999-06-14 2000-06-08 Composiciones farmaceuticas orales de liberacion controlada de mesalazina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02026576T Expired - Lifetime ES2262749T3 (es) 1999-06-14 2000-06-08 Composiciones farmaceuticas orales de liberacion controlada de mesalazina.

Country Status (18)

Country Link
US (1) US6773720B1 (es)
EP (2) EP1198226B1 (es)
JP (2) JP4727875B2 (es)
CN (2) CN100448448C (es)
AT (2) ATE235234T1 (es)
AU (1) AU5077200A (es)
CA (1) CA2377299C (es)
DE (2) DE60001835T2 (es)
DK (2) DK1198226T3 (es)
ES (2) ES2262749T3 (es)
HK (1) HK1046247B (es)
IT (1) ITMI991316A1 (es)
MX (1) MXPA01012888A (es)
NO (1) NO329402B1 (es)
PT (2) PT1198226E (es)
RU (1) RU2245148C2 (es)
TR (1) TR200200561T2 (es)
WO (1) WO2000076481A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
GB0322848D0 (en) * 2003-09-30 2003-10-29 Alpharma Ltd Tetracycline controlled release pharmaceutical dosage form
EP1715856B1 (en) * 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetine formulations
US7417037B2 (en) * 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009543873A (ja) * 2006-07-19 2009-12-10 ザ、ボード、アヴ、リージェンツ、アヴ、ズィ、ユーニヴァーサティ、アヴ、テクサス、システィム 炎症性腸疾患を治療するためのリン脂質および５−アミノサリチル酸を含有する医薬品の調製
AU2006348138A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis using aminosalicylate
US20100305076A1 (en) * 2006-09-13 2010-12-02 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis
PT2099446E (pt) 2006-11-17 2013-02-13 Shire Dev Inc Método de tratamento de doença inflamatória intestinal
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
US9463163B2 (en) 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
LT2661266T (lt) 2011-01-07 2020-12-10 Anji Pharma (Us) Llc Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CN104349773A (zh) 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
KR20230095124A (ko) 2012-01-06 2023-06-28 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
WO2013144176A1 (en) 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2722058A1 (en) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Solid oral composition containing dyes for use in endoscopic diagnosis
EA039530B1 (ru) 2013-01-05 2022-02-08 Анджи Фарма (Юс) Элэлси Композиция с отсроченным высвобождением, содержащая бигуанид
PT2959892T (pt) * 2013-02-22 2020-12-15 Zeria Pharm Co Ltd Comprimido com revestimento entérico
CN105307644B (zh) 2013-03-15 2019-07-23 沃纳奇尔科特有限责任公司 用于减少递送变化性的具有多种剂量单元的美沙拉嗪药物组合物
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
CN104922090B (zh) * 2015-07-03 2017-11-14 湖南方盛制药股份有限公司 美沙拉秦肠溶缓释微丸
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
AU2017364274A1 (en) 2016-11-28 2019-05-30 Cosmo Technologies Ltd. Solid oral composition containing dyes
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
CN112587506A (zh) * 2020-12-09 2021-04-02 南京森博医药研发有限公司 一种用于制备美沙拉嗪肠溶缓释胶囊的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
JPH02282323A (ja) * 1989-04-21 1990-11-19 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
JPH0624962A (ja) * 1992-07-09 1994-02-01 Green Cross Corp:The 腸溶徐放性製剤
WO1994008568A1 (fr) * 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
WO1998026767A2 (en) 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions

Also Published As

Publication number Publication date
AU5077200A (en) 2001-01-02
HK1085669A1 (zh) 2006-09-01
US6773720B1 (en) 2004-08-10
EP1287822B1 (en) 2006-04-26
HK1046247B (zh) 2006-04-07
DK1198226T3 (da) 2003-07-21
CN1355694A (zh) 2002-06-26
EP1287822A3 (en) 2003-03-19
NO20016107D0 (no) 2001-12-14
ES2262749T3 (es) 2006-12-01
MXPA01012888A (es) 2002-07-30
ITMI991316A1 (it) 2000-12-14
NO329402B1 (no) 2010-10-11
DE60027608T2 (de) 2007-04-26
JP2010024241A (ja) 2010-02-04
JP2003501458A (ja) 2003-01-14
ITMI991316A0 (it) 1999-06-14
EP1198226A1 (en) 2002-04-24
JP5235839B2 (ja) 2013-07-10
CA2377299C (en) 2009-05-12
NO20016107L (no) 2002-02-11
ATE235234T1 (de) 2003-04-15
EP1198226B1 (en) 2003-03-26
HK1046247A1 (en) 2003-01-03
PT1287822E (pt) 2006-07-31
CN1720919A (zh) 2006-01-18
DK1287822T3 (da) 2006-08-28
TR200200561T2 (tr) 2002-06-21
CA2377299A1 (en) 2000-12-21
ATE324104T1 (de) 2006-05-15
DE60027608D1 (de) 2006-06-01
DE60001835D1 (de) 2003-04-30
WO2000076481A1 (en) 2000-12-21
RU2245148C2 (ru) 2005-01-27
DE60001835T2 (de) 2003-11-13
CN1217665C (zh) 2005-09-07
CN100448448C (zh) 2009-01-07
EP1287822A2 (en) 2003-03-05
JP4727875B2 (ja) 2011-07-20
PT1198226E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CA2385890A1 (en) Controlled release compositions comprising nimesulide
GT199900203A (es) Composiciones de celecoxib.
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
ES2150404T1 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ECSP003685A (es) Formulaciones orales de liberacion controlada
DE60027601D1 (de) Arzneizubereitung mit kontrollierter freisetzung enthaltend tramadol hydrochlorid
MY141008A (en) Oral formulations of deoxypeganine and their uses
UY26176A1 (es) Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas.
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
HN1999000174A (es) Formulacion medicamentosa acuisa para administracion oral.
DE60029946D1 (de) Arzneimittel gegen glomerulosclerose
RU2002120047A (ru) Лекарственная форма, обладающая противотуберкулезным действием
CO4910116A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles
GT199700112A (es) Nuevas microesferas farmaceuticas para administracion oral.
GT200000207A (es) Composiciones de valdecoxib.